Compare HIG & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIG | TEVA |
|---|---|---|
| Founded | 1810 | 1901 |
| Country | United States | Israel |
| Employees | 19200 | 32842 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.3B | 33.5B |
| IPO Year | N/A | N/A |
| Metric | HIG | TEVA |
|---|---|---|
| Price | $138.73 | $31.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $149.38 | $38.63 |
| AVG Volume (30 Days) | 1.1M | ★ 5.2M |
| Earning Date | 04-23-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.06 | N/A |
| Revenue Next Year | $4.13 | $3.24 |
| P/E Ratio | ★ $10.61 | $28.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $113.27 | $13.04 |
| 52 Week High | $143.98 | $37.35 |
| Indicator | HIG | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 58.60 |
| Support Level | $129.04 | $30.70 |
| Resistance Level | $139.25 | $31.99 |
| Average True Range (ATR) | 2.46 | 0.94 |
| MACD | 0.61 | 0.37 |
| Stochastic Oscillator | 70.91 | 93.91 |
The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments, including Business Insurance, Personal Insurance, Property & Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.